Metlife Inc (MET) — Who's Buying and Selling (13F, Q2 2026)

MET ranks #250 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

1463 institutions disclose a position in MET, but none treat it as a major bet — even Pzena Investment Management LLC, its most concentrated holder, allocates just 2.8% of its own portfolio to it.

Arrowstreet Capital, Limited Partnership has added to its MET position for two straight quarters, increasing it by $386.7M to reach $491.5M today.

Ameriprise Financial Inc has trimmed its MET position for two straight quarters, cutting it by $254.6M while still holding $294.0M.

MET is down 0.8% today, but institutions show net buying of $5.8B this quarter — a divergence between today's price move and the underlying institutional flow.

MET posted net income of $3.6B over the trailing twelve months.

• Profitable — net income of $3.6B over the trailing twelve months
• Revenue grew 15.2% year over year
• Net income declined year over year, from $4.3B to $3.6B
• Generated $17.1B in positive operating cash flow
• Liabilities run 25.22x equity — a highly leveraged balance sheet worth noting